Physician profile
Deepak Vadhan
NPI 1245314954
$10,559.60
in general payments reported to CMS, 2019-2025
25 companies · $1,827 in 2025
The $1,827 reported for 2025 was more than what 86% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $729 · 2021: $999 · 2022: $1,933 · 2023: $1,786 · 2024: $1,936 · 2025: $1,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,463 · Education: $86.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,462.69 |
| Education | $86.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,250.07 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,956.67 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,282.86 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Regeneron Healthcare Solutions, INC. | $697.29 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $565.20 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Insmed, INC. | $435.53 | 2019-2025 | Arikayce, Brinsupri |
| Electromed, INC. | $367.01 | 2021-2025 | Smartvest |
| Mallinckrodt Enterprises LLC | $339.23 | 2019 | |
| Amgen INC. | $332.73 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $248.27 | 2019-2023 | Opsumit |
| Advanced Respiratory, INC | $231.71 | 2019-2021 | |
| Genzyme Corporation | $179.45 | 2021-2025 | |
| Philips North America LLC | $121.87 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Paratek Pharmaceuticals, INC. | $97.42 | 2021-2024 | Nuzyra |
| Mallinckrodt Hospital Products INC. | $90.65 | 2021-2025 | Acthar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $88.13 | 2020-2023 | Yupelri |
| Verona Pharma, INC. | $51.93 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $50.06 | 2019-2020 | |
| Novo Nordisk INC | $46.45 | 2020 | |
| Inspire Medical Systems, INC. | $30.80 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $29.30 | 2019 | |
| Intra-Sana Laboratories | $20.37 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Janssen Pharmaceuticals, INC | $18.78 | 2021 | |
| Baxter Healthcare | $16.39 | 2023 | Hillrom - Life 2000 Ventilation System |
| Teva Pharmaceuticals USA, INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Vadhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.